KR-39038

KR-39038 is an orally active and potent GRK5 (G protein-coupled receptor kinase 5) inhibitor, with an IC 50 of 0.02 μM. KR-39038 significantly inhibits angiotensin II-induced cellular hypertrophy through suppression of HDAC5 pathway in neonatal cardiomyocytes. KR-39038 shows profound anti-hypertrophic effects and improved cardiac function. KR-39038 can be used for heart failure research In Vitro KR-39038 (0-1.0 μM, 24 h) significantly inhibits angiotensin II-induced cellular hypertrophy and HDAC5 phosphorylation in neonatal cardiomyocytes. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: Primary neonatal cardiomyocytes (isolated from S.D. rats (1-2 days old) using primary myocardial cell isolation kit) Concentration: 0 μM, 0.03 μM, 0.1 μM, 0.3 μM, 1.0 μM Incubation Time: 24 h Result: Significantly inhibited angiotensin II-induced cellular hypertrophy at a concentration of 0.1 µM and higher concentrations. Decreased angiotensin II-induced HDAC5 phosphorylation at 0.3 µM and higher concentrations. In Vivo KR-39038 (0-30 mg/kg, Orally, once daily for 14 days) effectively attenuates both cardiac hypertrophy and dysfunction in experimental heart failure . Pharmacokinetic Parameters of KR-39038 in Sprague-Dawley rats . Parameters IV (5 mg/kg) PO (300 mg/kg) C max (µg/mL) NA 5.2 ± 2.8 T max (h) NA 0.7 ± 0.2 t 1/2 (h) 0.7 ± 0.04 2.3 ± 2.9 AUC 0-∞ (µg*h/mL) 3.4 ± 1.0 8.9 ± 5.0 CL (L/h/kg) 1.6 ± 0.5 NA Vss (L/kg) 1.2 ± 0.2 NA F (%) 4.3 ± 2.4 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 mice (male, 20-24 g, transverse aortic constriction) Dosage: 30 mg/kg Administration: Orally, once a day for 2 weeks, starting from 24 h after the operation Result: Showed a 43% reduction in the left ventricular weight, and significantly attenuated the development of cardiac hypertrophy. Animal Model: Sprague-Dawley (S.D.) rats (male, 380-420 g, coronary artery ligation) Dosage: 10 mg/kg, 30 mg/kg Administration: Orally, once a day for 12 weeks, starting from 24 h after surgery Result: Showed significant preservation of cardiac function and attenuation of myocardial remodeling in a rat model of chronic heart failure following coronary artery ligation. Animal Model: Sprague-Dawley (S.D.) rats Dosage: 5 mg/kg (IV), 300 mg/kg (Orally) Administration: IV or Orally, single (Pharmacokinetic Analysis) Result: The AUC ∞ values after intravenous injection with 10 mg/kg and oral administration of 300 mg/kg of KR-39038 were 3.4 ± 1.0 and 8.9 ± 5.0 µg·h/mL, respectively, resulting in 4.3% bioavailability. Form:Solid IC50& Target:HDAC5

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet